10-Q: Nexien BioPharma Reports Q3 2024 Results: Operating Losses Continue Amidst Funding Challenges

Nexien BioPharma reports a net loss of $152,599 for the nine months ended March 31, 2024, highlighting ongoing financial challenges and the need for additional capital.

Summary

• Nexien BioPharma reported a net loss of $53,163 for the three months ended March 31, 2024, which is an improvement compared to the $79,853 loss in the same period of 2023.
• The company's net loss for the nine months ended March 31, 2024, was $152,599, a decrease from the $268,319 loss in the same period of 2023.
• General and administrative costs were $9,282 for the quarter and $63,548 for the nine months ended March 31, 2024, which included non-cash stock-based compensation.
• The company incurred $26,978 in discount related to convertible debt financings for the quarter and $35,941 for the nine months ended March 31, 2024.
• Interest expense was $10,238 for the quarter and $25,280 for the nine months ended March 31, 2024, including imputed interest on related party advances.
• There were no research and development costs for the periods ended March 31, 2024 and 2023 due to limited financial resources.
• The company had a working capital deficit of $325,291 and cash of $10,067 as of March 31, 2024.
• The company is seeking additional capital, merger, or other business combination opportunities due to its financial situation.
• The company estimates it needs at least $50,000 to maintain its public company status for the remainder of the fiscal year.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the company's significant financial challenges, lack of revenue, going concern issues, and the need for substantial additional capital. The company's future is highly uncertain.

Positives

• The company's net loss decreased for both the three and nine-month periods ended March 31, 2024, compared to the same periods in 2023.
• The company successfully raised $2.1 million in equity capital and $166,750 from debt issuances through March 31, 2024.
• The company has extended the maturity date of a convertible note with Richard Greenberg, providing some short-term financial relief.

Negatives

• The company continues to operate at a loss, with a net loss of $152,599 for the nine months ended March 31, 2024.
• The company has a significant working capital deficit of $325,291 as of March 31, 2024.
• The company has very limited cash reserves, with only $10,067 on hand as of March 31, 2024.
• The company had to cease research and development activities due to a lack of sufficient working capital.
• The company is heavily reliant on debt financing and related party transactions.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is highly dependent on raising additional capital.
• The company's drug development programs require substantial funding, and there is no guarantee of securing regulatory approvals.
• The company faces the risk of dilution for existing shareholders if it raises additional equity capital.
• The company's debt financing may subject it to restrictive covenants and significant interest costs.
• The company's internal controls over financial reporting were deemed ineffective as of March 31, 2024.
• The company is seeking merger or other business combination opportunities, which may not be successful.

Future Outlook

The company anticipates needing at least $50,000 to maintain its public company status for the remainder of the fiscal year and is seeking additional capital, merger, or other business combination opportunities.

Management Comments

• Management believes the information provided is relevant to an assessment and understanding of the company's results of operations and financial condition.
• Management acknowledges the substantial doubt about the company's ability to continue as a going concern without a significant infusion of capital or a business combination.
• Management continues its efforts to raise additional capital for the company and is also seeking merger or other business combination or restructuring opportunities.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on cannabinoid-based drug development, which is a high-risk, high-reward sector with significant regulatory hurdles and capital requirements. The company's financial struggles are not uncommon for early-stage biotech companies.

Comparison to Industry Standards

• Nexien BioPharma's financial situation is concerning when compared to industry standards for biotech companies. Many early-stage biotech firms rely on venture capital or private equity funding, which Nexien appears to lack.
• Companies like GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) and Canopy Growth have demonstrated the potential for success in the cannabinoid space, but they also had significant financial backing and resources.
• Nexien's lack of revenue and reliance on debt financing is not sustainable in the long term, and it needs to secure substantial funding to progress its drug development programs.
• Compared to other companies in the sector, Nexien's cash position is extremely weak, and its ability to continue as a going concern is highly questionable without a significant capital infusion.

Related Party Transactions

• The company's Chief Executive Officer advanced $8,400 to the company for working capital and operating purposes.
• The company has recorded imputed interest on advances from its CEO at a rate of 10%.
• The company issued shares of common stock to its officers as compensation for services.
• The company has convertible notes payable to its CEO and a shareholder.

Stakeholder Impact

• Shareholders face significant risk of dilution if the company raises additional equity capital.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and suppliers are not directly impacted at this stage due to the company's pre-revenue status.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company needs to secure additional funding to continue operations and drug development.
• The company is seeking merger or other business combination opportunities.
• The company needs to address the deficiencies in its internal controls over financial reporting.
• The company needs to continue discussions with Quick Capital for further extension of the convertible note.

Key Dates

Keywords

biopharmaceutical, cannabinoids, drug development, convertible debt, working capital, net loss, going concern, capital raise, financial statements, related party transactions